{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:01:45Z","timestamp":1788307305797,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["[218466\/Z\/19\/Z], studentship [319465\/Z\/24\/Z]"],"award-info":[{"award-number":["[218466\/Z\/19\/Z], studentship [319465\/Z\/24\/Z]"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Ovarian cancer is one of the most common gynaecological cancers affecting more than 300,000 women worldwide each year. S100 calcium-binding protein A6 (S100A6) is a member of the S100 family of calcium-binding proteins. Upon activation by calcium (Ca\n                      <jats:sup>2+<\/jats:sup>\n                      ) signalling, S100A6 regulates numerous cellular processes including cell proliferation and metastasis. The role of S100A6 is well established across multiple tumour types where increased S100A6 expression contributes to tumourigenesis and worse patient outcome. However, the role of S100A6 in ovarian cancer is not well established.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The impact of cytoplasmic and nuclear S100A6 expression on overall survival and clinicopathological criteria was investigated in 462 ovarian tumours by immunohistochemistry. Additionally,\n                      <jats:italic>S100A6<\/jats:italic>\n                      expression in an ovarian cancer cohort from The Cancer Genome Atlas (TCGA) PanCancer dataset (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009299) was evaluated and associations with overall survival and progression-free survival were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Immunohistochemical staining revealed that high cytoplasmic expression of S100A6 was significantly associated with better overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). Additionally, high nuclear expression was significantly associated with better overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036). In contrast, analysis of mRNA\n                      <jats:italic>S100A6<\/jats:italic>\n                      suggests no significant association of mRNA levels for overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.903) and progression free survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.278).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data provides novel insights regarding the clinical implications of S100A6 expression in ovarian cancer, providing strong rationale for functional investigations of S100A6 in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15631-0","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:23:57Z","timestamp":1770783837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Aruba","family":"Farooq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren M.","family":"Akyuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon WQ","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suha","family":"Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt\u00e9a J.","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Storr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"15631_CR1","doi-asserted-by":"publisher","unstructured":"Bray Bsc F et al. Laversanne | Mathieu, Hyuna |,. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u2013263. https:\/\/doi.org\/10.3322\/CAAC.21834.","DOI":"10.3322\/CAAC.21834"},{"key":"15631_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287. https:\/\/doi.org\/10.2147\/IJWH.S197604.","journal-title":"Int J Womens Health"},{"issue":"11","key":"15631_CR3","first-page":"937","volume":"93","author":"CA Doubeni","year":"2016","unstructured":"Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93(11):937\u201344. https:\/\/www.aafp.org\/pubs\/afp\/issues\/2016\/0601\/p937.html. Accessed September 3, 2024.","journal-title":"Am Fam Physician"},{"issue":"24","key":"15631_CR4","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","volume":"34","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888\u201398. https:\/\/doi.org\/10.1200\/JCO.2016.66.8178.","journal-title":"J Clin Oncol"},{"key":"15631_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2016.61.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"15631_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/S12943-024-02073-0\/FIGURES\/7","volume":"23","author":"A Moniot","year":"2024","unstructured":"Moniot A, Schneider C, Chardin L, et al. The CD47\/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research. Mol Cancer. 2024;23(1):166. https:\/\/doi.org\/10.1186\/S12943-024-02073-0\/FIGURES\/7.","journal-title":"Mol Cancer"},{"key":"15631_CR7","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.2147\/CMAR.S292992","volume":"13","author":"T Guo","year":"2021","unstructured":"Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L. Cellular mechanism of gene mutations and potential therapeutic targets in ovarian cancer. Cancer Manag Res Dove Med Press Ltd. 2021;13:3081\u2013100. https:\/\/doi.org\/10.2147\/CMAR.S292992.","journal-title":"Cancer Manag Res Dove Med Press Ltd"},{"issue":"3","key":"15631_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/CJP2.311","volume":"9","author":"M K\u00f6bel","year":"2023","unstructured":"K\u00f6bel M, Kang EY, Weir A, et al. p53 and ovarian carcinoma survival: an ovarian tumor tissue analysis consortium study. J Pathol Clin Res. 2023;9(3):208. https:\/\/doi.org\/10.1002\/CJP2.311.","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"15631_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/J.ADVENZREG.2007.11.001","volume":"48","author":"A Filipek","year":"2008","unstructured":"Filipek A, Michowski W, Kuznicki J. Involvement of S100A6 (calcyclin) and its binding partners in intracellular signaling pathways. Adv Enzyme Regul. 2008;48(1):225\u201339. https:\/\/doi.org\/10.1016\/J.ADVENZREG.2007.11.001.","journal-title":"Adv Enzyme Regul"},{"issue":"2","key":"15631_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc3893","volume":"15","author":"AR Bresnick","year":"2015","unstructured":"Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15(2):96\u2013109. https:\/\/doi.org\/10.1038\/nrc3893.","journal-title":"Nat Rev Cancer"},{"key":"15631_CR11","doi-asserted-by":"crossref","unstructured":"Kuznicki J, Filipek A. Purification and properties of a novel Ca2+-Binding protein (10.5 KDa) from Ehrlich-Ascites-Tumour Cells*. 247.; 1987. http:\/\/portlandpress.com\/biochemj\/article-pdf\/247\/3\/663\/592275\/bj2470663.pdf.","DOI":"10.1042\/bj2470663"},{"issue":"4","key":"15631_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/J.BBRC.2009.10.150","volume":"390","author":"W Le\u015bniak","year":"2009","unstructured":"Le\u015bniak W, S\u0142omnicki \u0141P, Filipek A. S100A6 \u2013 new facts and features. Biochem Biophys Res Commun. 2009;390(4):1087\u201392. https:\/\/doi.org\/10.1016\/J.BBRC.2009.10.150.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"15631_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40364-023-00515-3","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang Y, Kang X, Kang X, Yang F. S100A6: molecular function and biomarker role. Biomark Res. 2023;11(1):1\u201314. https:\/\/doi.org\/10.1186\/S40364-023-00515-3.","journal-title":"Biomark Res"},{"issue":"44","key":"15631_CR14","doi-asserted-by":"publisher","first-page":"31593","DOI":"10.1074\/jbc.274.44.31593","volume":"274","author":"TB Stradal","year":"1999","unstructured":"Stradal TB, Gimona M. Ca2+-dependent association of S100A6 (calcyclin) with the plasma membrane and the nuclear envelope. J Biol Chem. 1999;274(44):31593\u20136. https:\/\/doi.org\/10.1074\/jbc.274.44.31593.","journal-title":"J Biol Chem"},{"issue":"2","key":"15631_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24021341","volume":"24","author":"W Le\u015bniak","year":"2023","unstructured":"Le\u015bniak W, Filipek A. S100A6 protein\u2014expression and function in norm and pathology. International Journal of Molecular Sciences 2023, Vol 24, Page 1341. Int J Mol Sci. 2023;24(2):1341. https:\/\/doi.org\/10.3390\/IJMS24021341.","journal-title":"Int J Mol Sci"},{"key":"15631_CR16","doi-asserted-by":"crossref","unstructured":"Jastrz B, Filipek A, Nowicka D, Kaczmarek L, Ku J. Calcyclin (S100A6) Binding Protein (CacyBP) Is Highly Expressed in Brain Neurons. 2000;48. http:\/\/www.jhc.org.","DOI":"10.1177\/002215540004800903"},{"issue":"4","key":"15631_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1055-9965.EPI-06-0157","volume":"16","author":"K Ohuchida","year":"2007","unstructured":"Ohuchida K, Mizumoto K, Yu J, et al. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev. 2007;16(4):649\u201354. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0157.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"15631_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0014-4827(92)90191-A","volume":"200","author":"J Ku\u017anicki","year":"1992","unstructured":"Ku\u017anicki J, Kordowska J, Puzianowska M, Wo\u017aniewicz BM. Calcyclin as a marker of human epithelial cells and fibroblasts. Exp Cell Res. 1992;200(2):425\u201330. https:\/\/doi.org\/10.1016\/0014-4827(92)90191-A.","journal-title":"Exp Cell Res"},{"issue":"10","key":"15631_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1515\/hsz-2017-0125","volume":"398","author":"W Le\u015bniak","year":"2017","unstructured":"Le\u015bniak W, Wilanowski T, Filipek A. S100A6 - focus on recent developments. Biol Chem Walter De Gruyter GmbH. 2017;398(10):1087\u201394. https:\/\/doi.org\/10.1515\/hsz-2017-0125.","journal-title":"Biol Chem Walter De Gruyter GmbH"},{"issue":"4","key":"15631_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/J.BIOCEL.2008.08.007","volume":"41","author":"\u0141P S\u0142omnicki","year":"2009","unstructured":"S\u0142omnicki \u0141P, Nawrot B, Le\u015bniak W. S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol. 2009;41(4):784\u201390. https:\/\/doi.org\/10.1016\/J.BIOCEL.2008.08.007.","journal-title":"Int J Biochem Cell Biol"},{"issue":"43","key":"15631_CR21","doi-asserted-by":"publisher","first-page":"31317","DOI":"10.1074\/jbc.M703951200","volume":"282","author":"E Leclerc","year":"2007","unstructured":"Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem. 2007;282(43):31317\u201331. https:\/\/doi.org\/10.1074\/jbc.M703951200.","journal-title":"J Biol Chem"},{"issue":"3","key":"15631_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.18388\/PB.2018_136","volume":"64","author":"A Filipek","year":"2018","unstructured":"Filipek A, Le\u015bniak W. Current view on cellular function of S100A6 and its ligands, CacyBP\/SIP and Sgt1. Postepy Biochem. 2018;64(3):242\u201352. https:\/\/doi.org\/10.18388\/PB.2018_136.","journal-title":"Postepy Biochem"},{"issue":"9","key":"15631_CR23","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/JOG.12729","volume":"41","author":"Z Liu","year":"2015","unstructured":"Liu Z, Zhang X, Chen M, Cao Q, Huang D. Effect of S100A6 over-expression on \u03b2-catenin in endometriosis. J Obstet Gynaecol Res. 2015;41(9):1457\u201362. https:\/\/doi.org\/10.1111\/JOG.12729.","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"15631_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0121319","volume":"10","author":"X Chen","year":"2015","unstructured":"Chen X, Liu X, Lang H, Zhang S, Luo Y, Zhang J. S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through \u03b2-catenin in pancreatic cancer cell line. PLoS One. 2015;10(3):e0121319. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0121319.","journal-title":"PLoS One"},{"key":"15631_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biom13071139","author":"F Yang","year":"2023","unstructured":"Yang F, Ma J, Zhu D, et al. The role of S100A6 in human diseases: molecular mechanisms and therapeutic potential. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13071139.","journal-title":"Biomolecules"},{"issue":"7","key":"15631_CR26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.bjc.6605289","volume":"101","author":"T Nedjadi","year":"2009","unstructured":"Nedjadi T, Kitteringham N, Campbell F, et al. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 2009;101(7):1145\u201354. https:\/\/doi.org\/10.1038\/sj.bjc.6605289.","journal-title":"Br J Cancer"},{"issue":"21","key":"15631_CR27","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-05-0714","volume":"11","author":"K Ohuchida","year":"2005","unstructured":"Ohuchida K, Mizumoto K, Ishikawa N, et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 2005;11(21):7785\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0714.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"15631_CR28","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1111\/jcmm.16343","volume":"25","author":"H Zhuang","year":"2021","unstructured":"Zhuang H, Chen X, Dong F, et al. Prognostic values and immune suppression of the S100A family in pancreatic cancer. J Cell Mol Med. 2021;25(6):3006\u201318. https:\/\/doi.org\/10.1111\/jcmm.16343.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"15631_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/S00109-013-1104-3\/FIGURES\/7","volume":"92","author":"Z Li","year":"2014","unstructured":"Li Z, Tang M, Ling B, et al. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. J Mol Med (Berl). 2014;92(3):291\u2013303. https:\/\/doi.org\/10.1007\/S00109-013-1104-3\/FIGURES\/7.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"15631_CR30","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.3892\/ol.2018.8018","volume":"15","author":"A Li","year":"2018","unstructured":"Li A, Gu Y, Li X, et al. S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3k\/Akt signaling pathway. Oncol Lett. 2018;15(4):5685\u201393. https:\/\/doi.org\/10.3892\/ol.2018.8018.","journal-title":"Oncol Lett"},{"issue":"2","key":"15631_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2353\/AJPATH.2010.091217","volume":"177","author":"XH Wang","year":"2010","unstructured":"Wang XH, Zhang LH, Zhong XY, et al. S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am J Pathol. 2010;177(2):586\u201397. https:\/\/doi.org\/10.2353\/AJPATH.2010.091217.","journal-title":"Am J Pathol"},{"issue":"1","key":"15631_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3892\/ol.2016.5419","volume":"13","author":"XH Wang","year":"2017","unstructured":"Wang XH, Du H, Li L, et al. Increased expression of S100A6 promotes cell proliferation in gastric cancer cells. Oncol Lett. 2017;13(1):222\u201330. https:\/\/doi.org\/10.3892\/ol.2016.5419.","journal-title":"Oncol Lett"},{"key":"15631_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-018-5170-3","author":"Y Bai","year":"2018","unstructured":"Bai Y, Li LD, Li J, Lu X. Prognostic values of S100 family members in ovarian cancer patients. BMC Cancer. 2018. https:\/\/doi.org\/10.1186\/S12885-018-5170-3.","journal-title":"BMC Cancer"},{"key":"15631_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0007670","author":"BR Wei","year":"2009","unstructured":"Wei BR, Hoover SB, Ross MM, et al. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One. 2009. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0007670.","journal-title":"PLoS One"},{"issue":"16","key":"15631_CR35","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.1111\/jcmm.15553","volume":"24","author":"SG Martin","year":"2020","unstructured":"Martin SG, Zhang S, Yang S, Saidy B, Deen S, Storr SJ. Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32), protein phosphatase-1 and cyclin-dependent kinase 5 expression in ovarian cancer. J Cell Mol Med. 2020;24(16):9165\u201375. https:\/\/doi.org\/10.1111\/jcmm.15553.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"15631_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/SJ.BJC.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer. 2005;93(4):387. https:\/\/doi.org\/10.1038\/SJ.BJC.6602678.","journal-title":"Br J Cancer"},{"issue":"2","key":"15631_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/J.CELL.2018.03.022\/ATTACHMENT\/C44C72C5-50F4-4BB9-9168-9F121ED94AED\/MMC9.XLSX","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, et al. Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291\u2013e3046. https:\/\/doi.org\/10.1016\/J.CELL.2018.03.022\/ATTACHMENT\/C44C72C5-50F4-4BB9-9168-9F121ED94AED\/MMC9.XLSX.","journal-title":"Cell"},{"issue":"21","key":"15631_CR38","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tilea new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713.","journal-title":"Clin Cancer Res"},{"issue":"D1","key":"15631_CR39","doi-asserted-by":"publisher","first-page":"D1334","DOI":"10.1093\/NAR\/GKAB970","volume":"50","author":"G Tang","year":"2022","unstructured":"Tang G, Cho M, Wang X. OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res. 2022;50(D1):D1334\u20139. https:\/\/doi.org\/10.1093\/NAR\/GKAB970.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"15631_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):1\u201312. https:\/\/doi.org\/10.3390\/IJMS22052622.","journal-title":"Int J Mol Sci"},{"key":"15631_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/J.XINN.2024.100625","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024. https:\/\/doi.org\/10.1016\/J.XINN.2024.100625.","journal-title":"Innovation"},{"issue":"Suppl 5","key":"15631_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/S12920-019-0514-7","volume":"12","author":"SJ Park","year":"2019","unstructured":"Park SJ, Yoon BH, Kim SK, Kim SY. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics. 2019;12(Suppl 5):101. https:\/\/doi.org\/10.1186\/S12920-019-0514-7.","journal-title":"BMC Med Genomics"},{"issue":"2","key":"15631_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.yexmp.2013.08.004","volume":"95","author":"M Rechsteiner","year":"2013","unstructured":"Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013;95(2):235\u201341. https:\/\/doi.org\/10.1016\/j.yexmp.2013.08.004.","journal-title":"Exp Mol Pathol"},{"issue":"6","key":"15631_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.21037\/TCR.2016.08.40","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Cao L, Nguyen D, Lu H. TP53 mutations in epithelial ovarian cancer. Transl Cancer Res. 2016;5(6):650. https:\/\/doi.org\/10.21037\/TCR.2016.08.40.","journal-title":"Transl Cancer Res"},{"issue":"47","key":"15631_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022777","volume":"99","author":"HY Xu","year":"2020","unstructured":"Xu HY, Song HM, Zhou Q. Comprehensive analysis of the expression and prognosis for S100 in human ovarian cancer: a STROBE study. Medicine. 2020;99(47):E22777. https:\/\/doi.org\/10.1097\/MD.0000000000022777.","journal-title":"Medicine"},{"key":"15631_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01657-w","author":"M Qi","year":"2023","unstructured":"Qi M, Yi X, Yue B, Huang M, Zhou S, Xiong J. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy. Breast Cancer Res. 2023. https:\/\/doi.org\/10.1186\/s13058-023-01657-w.","journal-title":"Breast Cancer Res"},{"issue":"21","key":"15631_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS21218323","volume":"21","author":"S Patergnani","year":"2020","unstructured":"Patergnani S, Danese A, Bouhamida E, et al. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. Int J Mol Sci. 2020;21(21):8323. https:\/\/doi.org\/10.3390\/IJMS21218323.","journal-title":"Int J Mol Sci"},{"key":"15631_CR48","doi-asserted-by":"publisher","DOI":"10.3892\/IJO.2023.5573","author":"F Deng","year":"2023","unstructured":"Deng F, Fu M, Zhao C, et al. Calcium signals and potential therapy targets in ovarian cancer (review). Int J Oncol. 2023. https:\/\/doi.org\/10.3892\/IJO.2023.5573.","journal-title":"Int J Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15631-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:03:56Z","timestamp":1781633036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15631-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15631"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15631-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from Derbyshire Ethics Committee (07\/H0401\/156). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.All samples collected from Nottingham used in this study were pseudo-anonymized; those collected prior to 2006 did not require informed patient consent under the Human Tissue Act; after 2006, informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}